Table 4. Mortality by HIV status and potential explanatory factors.
| HIV-uninfected | HIV infected | ||||||
| Factor | Level | n | Deaths | Mortality rate per 100 pyo (95% c.i.) | n | deaths | Mortality rate per 100 pyo (95% c.i.) |
| Overall | 32 | 11 | 19.7 (10.9; 35.5) | 64 | 41 | 46.9 (34.6; 63.7) | |
| Age | <30 | 20 | 5 | 13.2 (5.5; 31.9) | 28 | 17 | 40.1 (24.9; 64.5) |
| (years) | 30–40 | 5 | 3 | 43.0 (13.9; 133) | 26 | 19 | 70.0 (44.7; 109) |
| >40 | 7 | 3 | 26.7 (8.6; 82.7) | 10 | 5 | 28.1 (11.7; 67.4) | |
| Sex | Female | 7 | 2 | 13.0 (3.2; 51.9) | 39 | 25 | 44.8 (30.3; 66.3) |
| Male | 25 | 9 | 22.2 (11.6; 42.7) | 25 | 16 | 50.7 (31.1; 82.8) | |
| BMI1 (kg/m2) | ≤15 | 8 | 2 | 15.2 (3.8; 61.0) | 17 | 10 | 33.9 (18.2; 63.0) |
| >15–18.5 | 12 | 4 | 19.3 (7.2; 51.4) | 34 | 20 | 41.7 (26.9; 64.7) | |
| >18.5 | 12 | 5 | 22.7 (9.4; 54.5) | 12 | 10 | 111 (59.8; 206) | |
| Karnofsky Score | 70 + | 20 | 2 | 4.6 (1.1; 18.4) | 36 | 16 | 26.3 (16.1; 42.9) |
| ≤ 60 | 12 | 9 | 72.6 (37.8; 139) | 28 | 25 | 94.6 (63.9; 140) | |
| Resistance Status | Sens HR | 29 | 10 | 19.6 (10.6; 36.5) | 60 | 38 | 45.2 (32.9; 62.1) |
| Res H/R or both | 3 | 1 | 20.0 (2.8; 142) | 4 | 3 | 91.2 (29.4; 282) | |
| Sputum smear grade | 1+ or 2+ | 6 | 1 | 10.8 (1.5; 76.3) | 18 | 11 | 41.2 (22.8; 74.3) |
| 3+ | 5 | 1 | 8.0 (1.1; 56.6) | 11 | 9 | 72.0 (37.5; 138) | |
| 4+ | 21 | 9 | 26.4 (13.7; 50.8) | 35 | 21 | 43.6 (28.5; 66.9) | |
| Extent of disease on chest X-ray | Norm/Min | 0 | 0 | - | 21 | 14 | 64.6 (38.3; 109) |
| Moderate | 3 | 1 | 19.4 (2.7; 138) | 15 | 9 | 36.1 (18.8; 69.4) | |
| Severe | 28 | 10 | 21.2 (11.4; 39.5) | 27 | 17 | 43.8 (27.2; 70.4) | |
| Cavitation | No | 4 | 2 | 38.7 (9.7; 154) | 49 | 31 | 43.9 (30.9; 62.4) |
| Yes | 27 | 9 | 19.1 (10.0; 36.8) | 12 | 8 | 66.7 (33.3; 133) | |
| Duration of TB symptoms | <3 months | 11 | 3 | 14.7 (4.7; 45.5) | 40 | 27 | 49.9 (34.2; 72.8) |
| 3–6 months | 14 | 8 | 44.1 (22.1; 88.2) | 20 | 12 | 48.7 (27.7; 85.7) | |
| > 6 months | 7 | 0 | 0 | 4 | 2 | 23.3 (5.8; 93.1) | |
| DTP | ≥7 days | 14 | 2 | 5.9 (1.5; 23.6) | 32 | 19 | 40.7 (26.0; 63.8) |
| < 7 days | 18 | 9 | 40.9 (21.3; 78.6) | 32 | 22 | 54.1 (35.6; 82.1) | |
| ART & CD4 group | CD4≥200 | 8* | 3 | 17.0 (5.5; 52.7) | |||
| CD4 50–199, no Art | 18 | 12 | 76.5 (43.4; 130) | ||||
| CD4 50–199, ART | 7 | 1 | 4.9 (0.68; 34.5) | ||||
| CD4<50, no ART | 21 | 20 | 194 (120; 300) | ||||
| CD4<50. ART | 8 | 3 | 15.1 (4.9; 46.7) | ||||
| Adherence | Almost/fully | 15 | 2 | 6.4 (1.6; 25.4) | 36 | 23 | 40.0 (26.6; 60.2) |
| Missed half | 5 | 0 | 0 | 12 | 6 | 29.9 (13.4; 66.6) | |
| No Info | 12 | 9 | 114 (59.2; 218) | 16 | 12 | 122 (69.1; 214) |
* This is a time varying covariate; numbers are those for whom the category was their final category